TSXV:CZO

Stock Analysis Report

Executive Summary

Ceapro Inc., a biotechnology company, engages in developing and commercializing active ingredients in the United States, Canada, Germany, China, and internationally.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Ceapro is not covered by any analysts.

Share Price & News

How has Ceapro's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.3%

CZO

-0.3%

CA Chemicals

1.3%

CA Market


1 Year Return

-2.7%

CZO

-14.4%

CA Chemicals

-0.1%

CA Market

CZO outperformed the Chemicals industry which returned -14.4% over the past year.

CZO underperformed the Market in Canada which returned -0.1% over the past year.


Share holder returns

CZOIndustryMarket
7 Day-5.3%-0.3%1.3%
30 Day0%7.4%4.7%
90 Day9.1%-6.8%1.6%
1 Year-2.7%-2.7%-11.6%-14.4%3.4%-0.1%
3 Year-80.9%-80.9%9.9%3.7%19.1%8.4%
5 Year50.0%50.0%-33.8%-40.6%23.2%5.7%

Price Volatility Vs. Market

How volatile is Ceapro's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ceapro undervalued based on future cash flows and its price relative to the stock market?

1.25x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Ceapro to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Ceapro to establish if it is available at substantial discount.


Price Based on Earnings

Ceapro is loss making, we can't compare its value to the CA Chemicals industry average.

Ceapro is loss making, we can't compare the value of its earnings to the Canada market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Ceapro, we can't assess if its growth is good value.


Price Based on Value of Assets

Ceapro is overvalued based on assets compared to the CA Chemicals industry average.


Next Steps

Future Growth

How is Ceapro expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.8%

Forecasted Materials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ceapro has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Ceapro performed over the past 5 years?

-36.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Ceapro does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Ceapro's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Ceapro's 1-year growth to the CA Chemicals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Ceapro has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Ceapro has efficiently used its assets last year compared to the CA Chemicals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Ceapro improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Ceapro's financial position?


Financial Position Analysis

Ceapro is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Ceapro's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Ceapro's level of debt (1.9%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (318.2% vs 1.9% today).

Operating cash flow is negative therefore debt is not well covered.

Unable to confirm if the interest payments on Ceapro's debt are well covered by earnings due to lack of past financial data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 14x debt.


Next Steps

Dividend

What is Ceapro's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Ceapro's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Ceapro's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Ceapro has not reported any payouts.

Unable to verify if Ceapro's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Ceapro has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Ceapro's salary, the management and board of directors tenure and is there insider trading?

8.5yrs

Average board tenure


CEO

Gilles Gagnon (65yo)

7.2yrs

Tenure

CA$555,000

Compensation

Mr. Gilles R. Gagnon, M.Sc., MBA, ICD.D, serves as the President of Spectrum Pharma Canada Inc. (Spectrum Canada). Mr. Gagnon has been Chief Executive Officer and President of Ceapro Inc. since July 1, 201 ...


CEO Compensation Analysis

Gilles's remuneration is higher than average for companies of similar size in Canada.

Gilles's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

8.5yrs

Average Tenure

The tenure for the Ceapro board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Gilles Gagnon (65yo)

    CEO, President & Director

    • Tenure: 7.2yrs
    • Compensation: CA$555.00k
  • Stacy Prefontaine

    CFO & Corporate Secretary

    • Tenure: 4.3yrs
    • Compensation: CA$213.12k

Board Members

  • Gilles Gagnon (65yo)

    CEO, President & Director

    • Tenure: 7.2yrs
    • Compensation: CA$555.00k
  • Will Li (56yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: CA$32.40k
  • John Zupancic

    Independent Director

    • Tenure: 21.7yrs
    • Compensation: CA$30.00k
  • Don Oborowsky

    Independent Director

    • Tenure: 20.7yrs
    • Compensation: CA$25.00k
  • Glenn Rourke

    Chairman of the Board

    • Tenure: 4.9yrs
    • Compensation: CA$35.00k
  • Ulrich Kosciessa

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: CA$38.25k

Company Information

Ceapro Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ceapro Inc.
  • Ticker: CZO
  • Exchange: TSXV
  • Founded: 1997
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: CA$27.841m
  • Shares outstanding: 77.34m
  • Website: https://www.ceapro.com

Location

  • Ceapro Inc.
  • 7824 – 51 Avenue NW
  • Edmonton
  • Alberta
  • T6E 6W2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CZOTSXV (TSX Venture Exchange)YesClass A Voting Common SharesCACADSep 1988
CRPO.FOTCPK (Pink Sheets LLC)YesClass A Voting Common SharesUSUSDSep 1988
385DB (Deutsche Boerse AG)YesClass A Voting Common SharesDEEURSep 1988

Biography

Ceapro Inc., a biotechnology company, engages in developing and commercializing active ingredients in the United States, Canada, Germany, China, and internationally. The company is involved in the developm ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 23:33
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.